Nomura Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $92.1K | Sell |
382
-138
| -27% | -$30.2K | ﹤0.01% | 909 |
|
|
2026
Q1 | $98.3K | Hold |
520
| – | – | ﹤0.01% | 971 |
|
|
2025
Q4 | $88.4K | Hold |
520
| – | – | ﹤0.01% | 985 |
|
|
2025
Q3 | $68.5K | Hold |
520
| – | – | ﹤0.01% | 1029 |
|
|
2025
Q2 | $55.2K | Hold |
520
| – | – | ﹤0.01% | 1077 |
|
|
2025
Q1 | $64.6K | Sell |
520
-63
| -11% | -$8.22K | ﹤0.01% | 1030 |
|
|
2024
Q4 | $71.8K | Hold |
583
| – | – | ﹤0.01% | 1005 |
|
|
2024
Q3 | $65K | Hold |
583
| – | – | ﹤0.01% | 1020 |
|
|
2024
Q2 | $62.2K | Sell |
583
-15,740
| -96% | -$1.73M | ﹤0.01% | 1006 |
|
|
2024
Q1 | $1.97M | Buy |
16,323
+243
| +2% | +$29.8K | 0.01% | 724 |
|
|
2023
Q4 | $1.98M | Hold |
16,080
| – | – | 0.01% | 719 |
|
|
2023
Q3 | $2.08M | Buy |
16,080
+1,350
| +9% | +$180K | 0.01% | 703 |
|
|
2023
Q2 | $1.83M | Hold |
14,730
| – | – | 0.01% | 721 |
|
|
2023
Q1 | $2.16M | Hold |
14,730
| – | – | 0.01% | 683 |
|
|
2022
Q4 | $2.35M | Hold |
14,730
| – | – | 0.01% | 658 |
|
|
2022
Q3 | $1.96M | Buy |
14,730
+6
| +0% | +$912 | 0.01% | 677 |
|
|
2022
Q2 | $2.3M | Hold |
14,724
| – | – | 0.01% | 670 |
|
|
2022
Q1 | $2.29M | Buy |
14,724
+2,864
| +24% | +$416K | 0.01% | 699 |
|
|
2021
Q4 | $1.51M | Buy |
11,860
+240
| +2% | +$31.5K | 0.01% | 801 |
|
|
2021
Q3 | $1.51M | Hold |
11,620
| – | – | 0.01% | 770 |
|
|
2021
Q2 | $2.06M | Buy |
11,620
+1,600
| +16% | +$277K | 0.01% | 734 |
|
|
2021
Q1 | $1.65M | Sell |
10,020
-477
| -5% | -$78.5K | 0.01% | 751 |
|
|
2020
Q4 | $1.73M | Sell |
10,497
-3,604
| -26% | -$537K | 0.01% | 729 |
|
|
2020
Q3 | $2.01M | Buy |
14,101
+4,281
| +44% | +$531K | 0.02% | 618 |
|
|
2020
Q2 | $1.08M | Sell |
9,820
-3,724
| -27% | -$412K | 0.01% | 756 |
|
|
2020
Q1 | $1.35M | Buy |
13,544
+3,155
| +30% | +$408K | 0.01% | 629 |
|
|
2019
Q4 | $1.55M | Sell |
10,389
-1,164
| -10% | -$158K | 0.01% | 705 |
|
|
2019
Q3 | $1.48M | Buy |
11,553
+864
| +8% | +$116K | 0.01% | 676 |
|
|
2019
Q2 | $1.52M | Buy |
10,689
+1,939
| +22% | +$261K | 0.02% | 678 |
|
|
2019
Q1 | $1.25M | Buy |
8,750
+150
| +2% | +$19.6K | 0.01% | 709 |
|
|
2018
Q4 | $1.07M | Buy |
8,600
+800
| +10% | +$119K | 0.01% | 682 |
|
|
2018
Q3 | $1.31M | Hold |
7,800
| – | – | 0.01% | 676 |
|
|
2018
Q2 | $1.34M | Hold |
7,800
| – | – | 0.01% | 670 |
|
|
2018
Q1 | $1.18M | Buy |
7,800
+80
| +1% | +$11.7K | 0.01% | 688 |
|
|
2017
Q4 | $1.04M | Buy |
7,720
+900
| +13% | +$125K | 0.01% | 717 |
|
|
2017
Q3 | $997K | Hold |
6,820
| – | – | 0.01% | 691 |
|
|
2017
Q2 | $1.06M | Buy |
6,820
+270
| +4% | +$41.3K | 0.01% | 666 |
|
|
2017
Q1 | $951K | Buy |
6,550
+50
| +0.8% | +$6.51K | 0.01% | 696 |
|
|
2016
Q4 | $709K | Sell |
6,500
-600
| -8% | -$66.8K | 0.01% | 758 |
|
|
2016
Q3 | $863K | Buy |
7,100
+400
| +6% | +$53.9K | 0.02% | 694 |
|
|
2016
Q2 | $947K | Hold |
6,700
| – | – | 0.02% | 632 |
|
|
2016
Q1 | $875K | Buy |
6,700
+690
| +11% | +$85.9K | 0.02% | 666 |
|
|
2015
Q4 | $845K | Sell |
6,010
-3,040
| -34% | -$421K | 0.02% | 669 |
|
|
2015
Q3 | $1.2M | Buy |
9,050
+3,300
| +57% | +$568K | 0.02% | 529 |
|
|
2015
Q2 | $1.01M | Sell |
5,750
-150
| -3% | -$26.9K | 0.02% | 599 |
|
|
2015
Q1 | $1.02M | Sell |
5,900
-4,000
| -40% | -$687K | 0.02% | 605 |
|
|
2014
Q4 | $1.61M | Buy |
9,900
+4,900
| +98% | +$813K | 0.03% | 445 |
|
|
2014
Q3 | $803K | Hold |
5,000
| – | – | 0.01% | 643 |
|
|
2014
Q2 | $735K | Buy |
5,000
+2,000
| +67% | +$277K | 0.01% | 679 |
|
|
2014
Q1 | $416K | Buy |
+3,000
| New | +$452K | 0.01% | 788 |
|
Other funds holding JAZZ
Nomura Asset Management's JAZZ Position: Q2 2026 in Review
Nomura Asset Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 27% in Q2 2026, selling an estimated $30.2K and leaving 382 shares worth $92.1K. The position accounts for ﹤0.01% of the portfolio, ranked #909.
Nomura Asset Management first reported a position in JAZZ in Q1 2014 and has held it in 50 quarters since. The position peaked at $2.35M in Q4 2022. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- Nomura Asset Management held 382 shares of Jazz Pharmaceuticals worth $92.1K as of Q2 2026.
- Nomura Asset Management sold 138 Jazz Pharmaceuticals shares in Q2 2026, an estimated $30.2K.
- Jazz Pharmaceuticals made up ﹤0.01% of Nomura Asset Management's portfolio in Q2 2026, its #909 holding.
- Nomura Asset Management first reported a position in Jazz Pharmaceuticals in Q1 2014 and has held it in 50 quarters since.
- Nomura Asset Management's Jazz Pharmaceuticals position peaked at $2.35M in Q4 2022.
- 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on Nomura Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.